YE-PC8

YE-PC8 is an experimental oncolytic herpes simplex virus type-1 (HSV-1) engineered for the selective treatment of solid tumors, including glioma and hepatocellular carcinoma. Developed using bacterial artificial chromosome (BAC) recombineering, the virus is modified by replacing the viral ICP6 (UL39) gene—which encodes the large subunit of ribonucleotide reductase—with a cell cycle-regulatable luciferase transgene cassette. This genetic alteration renders the virus replication-deficient in normal, non-dividing cells while allowing it to selectively replicate in and lyse rapidly proliferating cancer cells that provide the necessary endogenous ribonucleotide reductase. Preclinical studies have demonstrated that YE-PC8 exhibits high tumor selectivity and potent anti-tumor activity, leading to significant tumor regression in human cancer xenograft models following intratumoral administration.